Spore Briefing Weekly: 2026-11-09 – 2026-11-15

Spore Briefing Weekly: 2026-11-09 – 2026-11-15

TLDR

  • Psychedelic-assisted therapies show promise for PTSD and depression, but evidence remains limited and preliminary.
  • A new review suggests psilocybin may help reduce alcohol use, though the data is still small and high-risk of bias.
  • Claims of “total ego-dissolution” during 5-MeO-DMT are being critically examined, with researchers arguing for a more nuanced view of self-consciousness.
  • Co-therapy in psychedelic-assisted therapy is being explored, but the evidence is anecdotal and not generalizable.
  • Epigenetic and neuroimmune mechanisms are being studied for their potential role in psychedelic effects, but these are still early-stage findings.

Biggest Study of the Week

A systematic review and meta-analysis in International Health Sciences Review looked at the clinical efficacy and safety of psilocybin- and MDMA-assisted therapies for treatment-resistant depression and PTSD. The review included randomized clinical trials, systematic reviews, and studies on mechanisms and safety from 2016 to 2026. The evidence was rated A, but the study is a narrative, non-systematic review, which weakens its reliability. It suggests that both psilocybin and MDMA may help reduce symptoms in controlled settings, but does not prove long-term effectiveness or safety for all individuals, especially those with pre-existing mental health conditions.

Source: International Health Sciences Review

Most Overhyped Headline

The article “Psychedelic ego-dissolution: a philosophical and qualitative critique” has been overhyped as a definitive refutation of ego-dissolution claims. However, the study is a philosophical and qualitative critique, not an empirical one. It analyzes 411 trip reports and critiques the interpretation of self-consciousness during 5-MeO-DMT experiences. The authors argue that total selflessness may be an overstatement, but they do not prove or disprove the claim with scientific evidence. This is a commentary, not a clinical trial or a controlled study.

Source: Europe PMC

Functional Mushroom Watch

This week, no functional mushroom studies stood out. Research on psilocybin, LSD, and DMT dominated the headlines, but no major findings emerged from the mushroom-based functional health space. The evidence grade for most studies remains low, and long-term benefits are still unproven. While mushrooms continue to be a source of interest, the science is still in its infancy.

Psychedelic Research Watch

A systematic review and meta-analysis of psilocybin-assisted therapy (PAT) for alcohol use disorder (AUD) found significant reductions in drinking outcomes and higher abstinence rates compared to controls. However, the evidence grade is A, but the risk of bias is high due to small sample sizes and limited trials. The study suggests that PAT may be helpful, but it does not prove its effectiveness or safety for all individuals.

Source: Europe PMC

Clinical Trial Watch

An analysis of participant perspectives on co-therapy in psychedelic-assisted therapy (PAT) for Generalised Anxiety Disorder (GAD) found that co-therapy on dose day provided safety and trust, but the study is based on qualitative interviews with 18 participants. The evidence grade is F, meaning it’s a commentary rather than a primary research study. While the findings are interesting, they are not generalizable and lack statistical rigor.

Source: Europe PMC

DMT / Consciousness Watch

A philosophical critique of ego-dissolution during 5-MeO-DMT experiences argues that total selflessness is an overstatement. The study analyzes 411 trip reports and suggests that minimal self-consciousness may still be present. However, the evidence is low-grade (D), based on qualitative interpretations and philosophical analysis, not controlled experiments. The findings are intriguing, but not definitive.

Source: Europe PMC

Don’t Get Scammed

Be cautious of claims that “total ego-dissolution” is a scientifically proven phenomenon. These are often based on subjective reports, not controlled studies. Also, be wary of studies that use small samples or qualitative methods to suggest efficacy without strong evidence. Always look for evidence grades A or B, randomized controlled trials, and peer-reviewed journals before taking claims at face value.

Best Content Opportunities

  1. “What’s Real About Psychedelic Ego-Dissolution?” – A short video comparing scientific and philosophical takes on ego-dissolution.
  2. “Psilocybin and Alcohol Use: Real or Overhyped?” – A quick explainer on the current state of the research.
  3. “Co-therapy in Psychedelic Assisted Therapy: What Do Patients Say?” – A short interview or compilation of participant quotes from the study.
  4. “Epigenetics and Psychedelics: The Long Game” – A deep dive into how psychedelics may influence gene expression, with a focus on the latest research.

Sources

Final Takeaway

This week’s research highlights both promising developments and persistent limitations in the psychedelic and mushroom spaces. While psilocybin and MDMA show potential in treating PTSD and depression, the evidence remains preliminary, and long-term outcomes are unknown. Studies on alcohol use, ego-dissolution, and co-therapy offer interesting insights, but methodological limitations and small sample sizes mean we should remain skeptical of overhyped claims. The science is advancing, but caution is still warranted.

Educational Disclaimer

This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.

If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.

Frequently asked questions

Is psilocybin-assisted therapy effective for treating depression?
Some studies suggest psilocybin may help reduce symptoms of depression in controlled settings, but the evidence is still limited and preliminary. Long-term effectiveness and safety for all individuals, especially those with pre-existing mental health conditions, remain unclear.
Can psychedelics like 5-MeO-DMT lead to total ego-dissolution?
Claims of total ego-dissolution during 5-MeO-DMT experiences are being critically examined, and researchers suggest that total selflessness may be an overstatement. The evidence is based on qualitative interpretations and philosophical analysis, not controlled experiments.
Are there any risks associated with psilocybin-assisted therapy for alcohol use disorder?
Psilocybin-assisted therapy may be helpful for reducing alcohol use, but the evidence is limited and at high risk of bias. Safety and long-term effectiveness for all individuals have not been proven.
What does the research say about co-therapy in psychedelic-assisted therapy?
Some participants report that co-therapy in psychedelic-assisted therapy provides a sense of safety and trust, but the evidence is anecdotal and not generalizable. More rigorous studies are needed to confirm these findings.
Is there scientific evidence that psychedelics affect epigenetics or the immune system?
Researchers are exploring potential epigenetic and neuroimmune mechanisms related to psychedelic effects, but these are still early-stage findings. There is currently no conclusive evidence to support these claims.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *